Literature DB >> 20832960

Release of proteolytic activity following reduction in therapeutic human serum albumin containing products: detection with a new neoepitope endopeptidase immunoassay.

Russell G A Jones1, Yvonne Liu, Chris Halls, Susan J Thorpe, Colin Longstaff, Paul Matejtschuk, Dorothea Sesardic.   

Abstract

Botulinum type A toxin (BoNT/A) is defined by its specific endopeptidase cleavage of SNAP25 between Gln(197) and Arg(198) under reducing conditions. The neurotoxin is widely used for therapeutic or cosmetic purposes, but should not contain other toxin serotypes or unwanted protease activities. Using a neoepitope endopeptidase immunoassay, additional cleavage between Arg(198) and Ala(199) was detected with a range of therapeutic BoNT/A products confirming an earlier report of an unidentified proteolytic component. By developing the assay and making it insensitive to BoNT/C1, any activity due to the type C1 toxin was excluded. Therapeutic preparations consist of ng quantities of toxin protein which are typically stabilised by 0.125-30 mg of HSA. An excellent correlation (R(2)=0.993) between HSA content per vial and measured activity was obtained within the therapeutic BoNT/A products tested. No activity was detected in any of the non-albumin formulated preparations, thereby identifying HSA as the source of the unknown protease for the first time. To investigate the cause of this activity, either as an intrinsic molecular activity of albumin or due to an albumin-associated purification contaminant, further studies on a variety of commercial plasma-derived HSA products or recombinant HSA materials free from potential plasma contaminants were carried out. The measured proteolytic levels were highly consistent amongst preparations, and could all be partially inhibited by the presence of zinc and blocked by PKSI-527 and aprotinin. By contrast, the data did not support the role of plasmin, kallikrein, trypsin, α(2)-antiplasmin-plasmin complexes or HSA purification contaminants, PKA (prekallikrein activator) or kallikrein-like activity. Taken together, these findings indicate a new intrinsic proteolytic activity of the albumin molecule revealed under reducing conditions as the source of the unexpected Arg-Ala cleaving activity.
Copyright © 2010 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20832960     DOI: 10.1016/j.jpba.2010.08.013

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  6 in total

1.  Protein modification by thiolactone homocysteine chemistry: a multifunctionalized human serum albumin theranostic.

Authors:  Tatyana V Popova; Olesya A Krumkacheva; Anna S Burmakova; Anna S Spitsyna; Olga D Zakharova; Vladimir A Lisitskiy; Igor A Kirilyuk; Vladimir N Silnikov; Michael K Bowman; Elena G Bagryanskaya; Tatyana S Godovikova
Journal:  RSC Med Chem       Date:  2020-04-02

Review 2.  Progress in cell based assays for botulinum neurotoxin detection.

Authors:  Sabine Pellett
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

3.  Human albumin prevents 6-hydroxydopamine-induced loss of tyrosine hydroxylase in in vitro and in vivo.

Authors:  Li-Juan Zhang; Yue-Qiang Xue; Chun Yang; Wei-Hua Yang; Long Chen; Qian-Jin Zhang; Ting-Yu Qu; Shile Huang; Li-Ru Zhao; Xiao-Min Wang; Wei-Ming Duan
Journal:  PLoS One       Date:  2012-07-17       Impact factor: 3.240

Review 4.  Biotoxin detection using cell-based sensors.

Authors:  Pratik Banerjee; Spyridon Kintzios; Balabhaskar Prabhakarpandian
Journal:  Toxins (Basel)       Date:  2013-11-29       Impact factor: 4.546

5.  A label free colorimetric assay for the detection of active botulinum neurotoxin type A by SNAP-25 conjugated colloidal gold.

Authors:  Jennifer Halliwell; Christopher Gwenin
Journal:  Toxins (Basel)       Date:  2013-08-06       Impact factor: 4.546

6.  Recommended Immunological Strategies to Screen for Botulinum Neurotoxin-Containing Samples.

Authors:  Stéphanie Simon; Uwe Fiebig; Yvonne Liu; Rob Tierney; Julie Dano; Sylvia Worbs; Tanja Endermann; Marie-Claire Nevers; Hervé Volland; Dorothea Sesardic; Martin B Dorner
Journal:  Toxins (Basel)       Date:  2015-11-26       Impact factor: 4.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.